BioSpace News Archive

Indiana University School of Medicine and Regenstrief Institute research scientists have received a $3.4 million award from the Patient-Centered Outcomes Research Institute (PCORI) to investigate the best care options for the 40 percent of people who go to the hospital emergency department with chest pain that is determined to be caused by anxiety rather than a cardiac event.

Acorda Therapeutics, Inc. (NASDAQ: ACOR) announced that Ron Cohen, M.D., President and Chief Executive Officer, will present during the January 11 th -14 th H.C. Wainwright BIOCONNECT Virtual Conference. An audio webcast of the presentation can be accessed under “Investor Events” in the Investor section of the Acorda website at www.acorda.com . For more information about the conference, please visit the event websi

Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today reported financial results for its first quarter of fiscal year 2021.

Omeros to Present at the 39 th Annual J.P. Morgan Healthcare Conference

RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC under which the underwriter has agreed to purchase on a firm commitment basis 1,275,510 American De

Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics™), today announced that clinical data from its Phase 1 dose escalation study of MCLA-158 will be presented in a poster session at the American Society of Clinical Oncology (ASCO) 2021 Gastrointestinal Cancers Symposium (ASCO G

− Goal to Reach JPY5 Trillion ($47 Billion) Revenue by FY2030 1 , Representing 50% Growth from FY2019 − Wave 1 Pipeline Portfolio Includes 12 New Molecular Entities Targeted for Launch by FY2024 Representing Best-in-Class/First-in-Class Therapies with Significant Market Potential − Rapid Deleveraging On Track to Achieve Target of 2x Net Debt / adjusted EBITDA within Fiscal Years 2021 to 2023

Panel can detect multiple variants of the SARS-CoV-2 virus, including those most recently identified in the United Kingdom, South Africa, and the U.S.

Gannex, a wholly owned company of Ascletis Pharma Inc. (HKEX: 1672) and fully dedicated to the R&D and commercialization of new drugs in the field of non-alcoholic steatohepatitis (NASH), today announces the positive phase I clinical results of ASC41

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market and the JASDAQ Market of the Tokyo Stock Exchange, announced that it has entered into a Securities Purchase Agreement pursuant to which MediciNova has agreed to issue US$20 million in shares of its common stock to 3D Opportunity Master Fund, a fund managed by 3D Investment Partners Pte.